This work sets the stage for future development of optimized CD4+-specific and CD8+-specific T cell responses in a personalized vaccine approach that will be essential for successful therapeutic outcomes in hard-to-treat cancer types such as pancreatic cancer. The gene discussed is CD4; the disease is pancreatic neoplasm.